AUG 13, 2017 12:52 PM PDT

Experimental Drug Slows Progression of Rare Genetic Disease

WRITTEN BY: Carmen Leitch

Researchers have identified a drug that has slowed the progression of a rare genetic disease in clinical trials. A fatal neurological disorder primarily affecting young people, Niemann-Pick disease type C1 (NPC1) is a degenerative disease in which cognitive and neurological functions progressively decline. The new work has been reported in the Lancet and is described in the following video.

The National Institutes of Health (NIH) is working with Sucampo Pharmaceuticals to cooperate on the development of the new drug, 2-hydroxypropyl-beta-cyclodextrin (VTS-270). A clinical trial compared two groups: one with 14 participants from four to 23 years old who received the drug once a month for 12 to 18 months, and another group of three who got the drug every two weeks for 18 months. Once it was seen that the more frequent doses were well tolerated, doses were increased for the other participants. The results were compared to the progress of patients in a previous study.

“The results are very encouraging and support continued development of VTS-270 for treating NPC1,” said Forbes D. Porter, M.D., Ph.D., clinical director at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the study’s senior author. “Compared to untreated patients we followed in an earlier study, participants who received VTS-270 scored better on a scale used to evaluate disease severity and progression, including elements such as speech, cognition, and mobility.”

The drug did not increase adverse outcomes for participants, although some patients with hearing loss did experience more hearing loss after treatment. Hearing aids were used to help these patients, and they could go on with a normal life.

Niemann-Pick disease type C1, a lipid storage disorder, as seen in a mouse cerebellum / Credit: NICHD

NPC1 causes a buildup of cholesterol in brain cells, resulting in the disease symptoms. The investigators thus assessed cholesterol metabolism in the study participants’ central nervous system and found a cholesterol metabolite. That suggested that the drug is improving the cholesterol metabolism dysfunction carried by the patients. The levels of two other molecules indicated that there was likely less damage occurring in the brain as well.

Patient neurological assessments demonstrated that the drug was slowing disease progression. Because of these encouraging results, the scientists are seeking to move on to another clinical trial, already approved by the FDA, to find the symptoms that the drug is targeting, and to refine the dosage. The ultimate goal, of course, is to bring this drug to all NPC1 patients who could benefit from it.

 

Sources: NIH, The Lancet

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAR 14, 2021
Cell & Molecular Biology
Modern Animals Still Have Similarities to Our Weird Ancient Ancestors
MAR 14, 2021
Modern Animals Still Have Similarities to Our Weird Ancient Ancestors
Recent research involving ancient marine animals shows how humans and other animals still carry some of those animals' c ...
MAR 15, 2021
Cell & Molecular Biology
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
MAR 15, 2021
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
Cells are packed full of organelles and molecules like proteins floating in a liquid known as cytoplasm. In recent years ...
MAR 21, 2021
Genetics & Genomics
Adding Evidence to the RNA World Hypothesis
MAR 21, 2021
Adding Evidence to the RNA World Hypothesis
Did life originate with RNA? Scientists are still trying to learn more about how the first molecules arose out of primor ...
APR 07, 2021
Plants & Animals
Scientists Discover a Crab-Dissolving Parasite
APR 07, 2021
Scientists Discover a Crab-Dissolving Parasite
Parasites abound throughout the natural world. While not all of them cause the host's death, this newly discovered p ...
APR 14, 2021
Cell & Molecular Biology
Repairing Traumatic Brain Injuries with 'Brain Glue'
APR 14, 2021
Repairing Traumatic Brain Injuries with 'Brain Glue'
Brain injuries are common, costly, and difficult to treat. The brain damage that accompanies a significant traumatic bra ...
APR 28, 2021
Plants & Animals
Insight Into the Evolution of Madagascar's 'Horned' Crocodile
APR 28, 2021
Insight Into the Evolution of Madagascar's 'Horned' Crocodile
Madagascar is home to many unusual animals. A skull from one - the 'horned' crocodile - can be seen in this image by M. ...
Loading Comments...